Viral prophylaxis treatment methods and pre-exposure prophylaxis kits

1. A method of pre-exposure prophylaxis against herpes simplex virus (HSV) infection in an HSV seronegative subject in need thereof, the method comprising orally administering to the subject daily a therapeutically effective amount of 0.5 mg/kg body weight to about 100 mg/kg body weight of an antiviral agent comprising acyclovir or a salt or solvate thereof, or valacyclovir or a salt or solvate thereof, or famciclovir or a salt or solvate thereof, or combinations thereof, whereby the risk of HSV infection in the subject is reduced.

2. The method of claim 1 wherein the antiviral agent comprises valacyclovir or a salt or solvate thereof.

3. The method of claim 1 wherein the antiviral agent comprises famciclovir or a salt or solvate thereof.

4. The method of claim 1 the antiviral agent comprises acyclovir or a salt or solvate thereof.

5. The method of claim 1 wherein the antiviral agent comprises valacyclovir or a salt or solvate thereof and famciclovir or a salt or solvate thereof.

6. The method of claim 1 , further comprising administering to the subject an effective amount of a contraceptive.

7. The method of claim 1 wherein the administering begins after physical contact with a partner who is seropositive for HSV.

8. The method of claim 1 wherein the administering begins prior to physical contact with the HSV seropositive partner.

9. The method of claim 7 , further comprising administering to the HSV seropositive partner a therapeutically effective amount of 0.5 mg/kg body weight to about 100 mg/kg body weight of an antiviral agent comprising acyclovir or a salt or solvate thereof, or valcyclovir or a salt or solvate thereof, or famciclovir or a salt or solvate thereof, or combinations thereof.

10. The method of claim 1 , wherein the antiviral agent comprises a sustained-release form.

11. The method of claim 7 , wherein the antiviral agent comprises a sustained release form.

12. The method of claim 1 additionally comprising a method of preventing HIV infection, said method further comprising administering to the subject a therapeutically effective amount of an HIV antiviral agent.

13. The method of claim 1 additionally comprising a method of preventing contraception, said method further comprising administering to the subject an effective amount of a contraceptive, and said subject is a female.

14. The method of claim 13 , provided that the contraceptive is an emergency contraceptive.

15. The method of claim 12 wherein the administering begins before physical contact with a partner who is seropositive for HIV and/or HSV.

16. The method of claim 15 , wherein the subject is seronegative for HIV.

17. The method of claim 15 , wherein the HSV seronegative subject is seropositive for HIV.

18. The method of claim 1 , wherein the antiviral agent comprises famciclovir and valacyclovir.

19. The method of claim 7 , wherein the antiviral agent comprises famciclovir and valacyclovir.

20. The method of claim 1 , wherein the administering includes administering an adjuvant.

21. The method of claim 7 , wherein the administering includes administering an adjuvant.

22. The method of claim 1 , 7 or 15 , wherein the therapeutically effective amount of the antiviral agent is from about 5 mg to about 2000 mg.

23. The method of claim 1 , 7 or 15 , wherein the therapeutically effective amount of valcicylovir is a daily dosage of about 200 mg to about 2500 mg.

24. The method of claim 1 , 7 or 15 , wherein the therapeutically effective amount of acyclovir is a daily dosage of about 200 mg to about 2000 mg.

25. The method of claim 1 , 7 or 15 , wherein the therapeutically effective amount of famciclovir is a daily dosage of about 400 mg to about 1000 mg.

26. The method of claim 1 , wherein the HSV is HSV-1.

27. The method of claim 1 , wherein the HSV is HSV-2.

28. The method of claim 7 , wherein the HSV is HSV-1.

29. The method of claim 7 , wherein the HSV is HSV-2.